Viviana Frantellizzi*, Mariano Pontico, Arianna Pani, Roberto Pani and Giuseppe De Vincentis Pages 1 - 5 ( 5 )
Background: To our knowledge, no previous study or literature review has been performed about the effects of the extravasation of therapeutic radiopharmaceutical agents and its potential consequences, especially regarding alpha-particle emitting radiopharmaceuticals.
Methods: Even if Radium-223 dichloride is known to be a relatively safe drug to manage, despite the correctness of the procedures applied , unexpected delayed adverse effects can occur.
In our vast experience, we rarely observed lymphedema ,even after some time, at the site of administration.
Results: Management of lymphedema caused by radiopharmaceuticals administration has been addressed through clinical examples. The sudden intervention allowed a fast remission of the signs and symptoms complained by patients treated with Radium-223 dichloride.
Conclusions: The management of adverse effects after radiopharmaceuticals administration as in case of lymphedema onset, is extremely simple. These data confirms the safety of Radium-223 treatment.
Ra-223 dichloride, alpha particle therapy, lymphedema, life quality, radiopharmaceutical adverse effects
Department of Molecular Medicine, Sapienza University of Rome, Rome, Ph.D. Program in Morphogenesis & Tissue Engineering, Sapienza University of Rome, Rome, Postgraduate School of Clinical Pharmacology and Toxicology, University of Milan “Statale”, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, Rome